Side Effects of Cytokines Approved for Therapy

Drug Safety

Volumn 37, Issue 11, 2014, Pages 921-943

  Baldo, Brian A ^a  

^a NONE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BECAPLERMIN; BETA1A INTERFERON; HEMOPOIETIC GROWTH FACTOR; METRELEPTIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PALIFERMIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEGYLATED CYTOKINE; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA1 INTERFERON; RECOMBINANT ALPHA2 INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT BETA INTERFERON; RECOMBINANT BETA1 INTERFERON; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT CYTOKINE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GAMMA INTERFERON; RECOMBINANT GAMMA1 INTERFERON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERFERON; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 11; RECOMBINANT INTERLEUKIN 2; RECOMBINANT OSTEOGENIC PROTEIN 1; RECOMBINANT PLATELET DERIVED GROWTH FACTOR; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; CYTOKINE; RECOMBINANT PROTEIN;

ABDOMINAL PAIN; ACUTE CHEST SYNDROME; ACUTE CORONARY SYNDROME; ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ACUTE KIDNEY FAILURE; ADULT RESPIRATORY DISTRESS SYNDROME; ALLERGY; ALOPECIA; ANAPHYLAXIS; ANEMIA; ANGIONEUROTIC EDEMA; ANOREXIA; ANXIETY DISORDER; AORTITIS; APPLICATION SITE BURNING; ARTHRALGIA; ASTHENIA; AUTOIMMUNE DISEASE; AUTOIMMUNE THROMBOCYTOPENIA; AUTOIMMUNE THYROIDITIS; BELL PALSY; BLOOD TOXICITY; BONE MARROW HYPOPLASIA; BONE PAIN; BRAIN ISCHEMIA; BRONCHOSPASM; BULLOUS SKIN DISEASE; CAPILLARY LEAK SYNDROME; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CELLULITIS; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; CHILL; CINCA SYNDROME; COGNITIVE DEFECT; COLITIS; CONFUSION; CONJUNCTIVAL HYPEREMIA; CORONARY ARTERY SPASM; COUGHING; CROHN DISEASE; CYTOKINE RELEASE; CYTOPENIA; DEEP VEIN THROMBOSIS; DELAYED HYPERSENSITIVITY; DEPRESSION; DESQUAMATION; DIABETIC NEUROPATHIC ULCER; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE EXACERBATION; DRUG APPROVAL; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DYSESTHESIA; DYSPNEA; ECCHYMOSIS; ECZEMA; EDEMA; EMOTIONAL DISORDER; ENDOCRINE DISEASE; EOSINOPHILIA; EOSINOPHILIC FASCIITIS; ERYTHEMA; ERYTHEMA MULTIFORME; ERYTHRODERMA; FATIGUE; FEVER; FIXED DRUG ERUPTION; FLU LIKE SYNDROME; GASTRITIS; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; GRANULOMATOUS INFLAMMATION; HAND FOOT SYNDROME; HASHIMOTO DISEASE; HEADACHE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART BLOCK; HEART DILATATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PALPITATION; HEART VENTRICLE TACHYCARDIA; HEMATOLOGIC DISEASE; HEMOLYSIS; HEMOLYTIC UREMIC SYNDROME; HEPATITIS B; HEPATITIS C; HETEROTOPIC OSSIFICATION; HUMAN; HYPERAMYLASEMIA; HYPERPIGMENTATION; HYPERTENSION; HYPERTHYROIDISM; HYPOGLYCEMIA; HYPOTENSION; HYPOTHYROIDISM; IMMUNOGLOBULIN A NEPHROPATHY; INFECTION; INJECTION SITE CELLULITIS; INJECTION SITE ERYTHEMA; INJECTION SITE INFLAMMATION; INJECTION SITE NECROSIS; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; INTERSTITIAL PNEUMONIA; INTERVERTEBRAL DISK DEGENERATION; IRON DEFICIENCY; ISCHEMIA; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY METASTASIS; KIDNEY TUBULE NECROSIS; LEPTIN DEFICIENCY; LEUKOPENIA; LICHEN PLANUS; LICHENOID ERUPTION; LIVEDO RETICULARIS; LIVER DISEASE; LUNG DISEASE; LUNG EDEMA; LUNG EMBOLISM; LUNG HEMORRHAGE; LUNG TOXICITY; LUNG TUBERCULOSIS; LUPUS LIKE SYNDROME; MACULOPAPULAR RASH; MALAISE; MANIA; MELANOMA; MENTAL DISEASE; METABOLIC DISORDER; METASTATIC MELANOMA; MIXED CONNECTIVE TISSUE DISEASE; MUCOSA INFLAMMATION; MULTIPLE ORGAN FAILURE; MULTIPLE SCLEROSIS; MYALGIA; MYELODYSPLASTIC SYNDROME; MYOCARDITIS; NAUSEA; NEOPLASM; NEPHROTIC SYNDROME; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUTROPENIA; NONHUMAN; OLIGURIA; ORAL MUCOSITIS; OSSIFYING MYOSITIS; OSTEOMYELITIS; OSTEOPOROSIS; PAPILLEDEMA; PARESTHESIA; PEMPHIGUS; PERICARDITIS; PERIPHERAL EDEMA; PERNICIOUS ANEMIA; PHYSICAL CHEMISTRY; PITYRIASIS ROSEA; PLEIOTROPY; PLEURA EFFUSION; PNEUMONIA; PRURITUS; PSEUDARTHROSIS; PSORIASIS; PSYCHOPATHY; PURE RED CELL ANEMIA; PUSTULOSIS PALMOPLANTARIS; PYOGENIC GRANULOMA; RADICULITIS; RADICULOPATHY; RASH; RAYNAUD PHENOMENON; RESPIRATORY DISTRESS; RESPIRATORY FAILURE; RESPIRATORY TRACT DISEASE; RESTLESS LEGS SYNDROME; RETROGRADE EJACULATION; REVIEW; RHEUMATOID ARTHRITIS; RHINITIS; RHINOPHARYNGITIS; RIGOR; SEIZURE; SENSORIMOTOR NEUROPATHY; SENSORY DYSFUNCTION; SEPTICEMIA; SICKLE CELL CRISIS; SIGNAL TRANSDUCTION; SINUSITIS; SKIN DISEASE; SKIN HYPERTROPHY; SKIN MANIFESTATION; SKIN TOXICITY; SKIN ULCER; SLEEP DISORDER; SOMNOLENCE; SPLEEN RUPTURE; SPLENOMEGALY; STAPHYLOCOCCUS INFECTION; STOMATITIS; SURGICAL INFECTION; SWELLING; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; T CELL LYMPHOMA; TACHYCARDIA; TASTE DISORDER; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; THRUSH; TONGUE DISCOLORATION; TONGUE DISEASE; TONGUE THICKENING; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME; TUMOR GROWTH; ULCER; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT DISEASE; UROGENITAL TRACT DISEASE; URTICARIA; VASCULITIS; VENOUS THROMBOEMBOLISM; VESICULAR RASH; VITILIGO; VIVID DREAM; VOMITING; WOUND COMPLICATION; XEROSIS;

CYTOKINES; DRUG APPROVAL; HUMANS; RECOMBINANT PROTEINS;

EID: 84910650219     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-014-0226-z     Document Type: Review

References (294)

1. FDA. CDER Therapeutic Biologic Products. CDER billable biologic product list. http://www.fda.gov/drugs/developmentapprovalprocess/druginnovation/default.htm. Accessed 1 June 2014.
2. FDA. User fee billable biologic products and potencies approved under section 351 of the PHS Act. http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CBER/ucm122936.htm. Accessed 1 June 2014.
3. Leader B, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov. 2008;7:21–39.
4. FDA. For Industry. Developing products for rare diseases and conditions. http://www.fda.gov/forindustry/DevelopingProductsforrareDiseasesConditions/default.htm. Accessed 1 June 2014.
5. Baldo BA, Pham NH. Drug allergy. Clinical aspects, diagnosis, mechanisms, structure-activity relationships. New York: Springer; 2013.
6. Ducancel F, Muller BH. Molecular engineering of antibodies for therapeutic and diagnostic purposes. mAbs 2012;4:445–57.
7. Kaneko E, Niwa R. Optimizing therapeutic antibody function: progress with Fc domain engineering. BioDrugs. 2011;25:1–11.
8. European Medicines Agency. Committee for medicinal products for human use. Guidelines on the clinical investigation of the pharmacokinetics of therapeutic proteins. 2005. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003031.pdf. Accessed 1 June 2014.
9. Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol. 2010;14:529–37.
10. Hansel TT, Kropshofer H, Singer T, et al. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 2010;9:325–38.
11. Baldo BA. Adverse events to monoclonal antibodies used for cancer therapy. Focus on hypersensitivity responses. OncoImmunology 2013;e26333. http://dx.doi.org/10.4161/onci.26333.
12. Dy GK, Adjei AA. Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin. 2013;63:249–79.
13. Baldo BA, Pagani M. Adverse events to non-targeted and targeted chemotherapeutic agents: emphasis on hypersensitivity responses. Immunol Allergy Clin N Am. 2014;34:565–96.
14. Vazquez-Lombardi R, Roome B, Christ D. Molecular engineering of therapeutic cytokines. Antibodies. 2013;2:426–51.
15. Vacchelli E, Eggermont A, Fridman WH, et al. Immunostimulatory cytokines. OncoImmunology. 2013;e24850. http://dx.doi.org/10.4161/onci.24850.
16. Wurm F, Bernard A. Large-scale transient expression in mammalian cells for recombinant protein production. Curr Opin Biotechnol. 1999;10:156–9.
17. Brannigan JA, Wilkinson AJ. Protein engineering 20 years on. Nature Rev Mol Cell Biol. 2002;3:964–70.
18. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Brit J Cancer. 2001;84(Suppl. 1):3–10.
19. Borish LC, Steinke JW. 2. Cytokines and chemokines. J Allergy Clin Immunol. 2003;111:S460–75.
20. Steinke JW, Borish L. 3. Cytokines and chemokines. J Allergy Clin Immunol. 2006;117:S441–5.
21. Tayal V, Kalra BS. Cytokines and anti-cytokines as therapeutics—an update. Eur J Pharmacol. 2008;579:1–12.
22. Vacchelli E, Galluzzi L, Eggermont A, et al. Immunostimulatory cytokines. OncoImmunology. 2012;1:493–506. http://dx.doi.org/10.4161/onci.20459.
23. Tato CM, Cua DJ. Snapshot: Cytokines I. Cell. 2008;132:324-e1.
24. Tato CM, Cua DJ. Snapshot: Cytokines II. Cell. 2008;132:500-e1.
25. Tato CM, Cua DJ. Snapshot: Cytokines III. Cell. 2008;132:900-e1.
26. Tato CM, Cua DJ. Snapshot: Cytokines IV. Cell. 2008;132:1062-e1.
27. Kyoto Encyclopedia of Genes and Genomes. http://www.genome.jp/kegg/.
28. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature. 2005;436:967–72.
29. ® (Peginterferon alfa-2a). FDA: Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103964s5204lbl.pdf. Accessed 1 June 2014.
30. ® (Peginterferon alfa-2a). EMA: Scientific discussion. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Scientific_Discussion/human/000395/WC500039192.pdf. Accessed 1 June 2014.
31. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. 2002;36:s237–44.
32. Constant A, Castera L, Dantzer R, et al. Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. J Clin Psychiatry. 2005;66:1050–7.
33. Negro F. Adverse effects of drugs in the treatment of viral hepatitis. Best Pract Res Clin Gastroenterol. 2010;24:183–92.
34. Poreaux C, Bronowicki J-P, Debouverie M, et al. Managing generalized interferon-induced eruptions and the effectiveness of desensitization. Clin Exp Allergy. 2014;44:756–64.
35. ®A (Interferon alfa-2b). FDA: Product information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/103132s5096lbl.pdf. Accessed 1 June 2014.
36. Kraus MR, Schäfer A, Faller H, et al. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry. 2003;64:708–14.
37. Laguno M, Murillas J, Blanco JL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS. 2004;18:F27–36.
38. Kraus MR, Schäfer A, Csef H, et al. Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C. World J Gastroenterol. 2005;11:1769–74.
39. ® (Peginterferon alfa-2b). FDA: Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/103949s5172lbl.pdf. Accessed 1 June 2014.
40. ® (Peginterferon alfa-2b). FDA: Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103949s5153lbl.pdf. Accessed 1 June 2014.
41. ® (Interferon beta-1a). FDA: Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103628s5189lbl.pdf. Accessed 1 June 2014.
42. Rudick RA, Ransohoff RM, Lee JC, et al. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis. Neurology. 1998;50:1294–300.
43. Walther EU, Hohlfeld R. Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology. 1999;53:1622–7.
44. Markowitz CE. Interferon-beta. Mechanism of action and dosing issues. Neurology. 2007;68(suppl 4):S8–11.
45. Kieseier BC. The mechanism of action of interferon-β in relapsing multiple sclerosis. CNS Drugs. 2011;25:491–502.
46. ® (Interferon beta-1b). FDA: Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103471s5185lbl.pdf. Accessed 5 June 2014.
47. ® (Interferon gamma-1b). FDA: Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/103836s5098LBL.pdf. Accessed 5 June 2014.
48. Ealick SE, Cook WJ, Vijay-Kumar S, et al. Three-dimensional structure of recombinant human interferon-gamma. Science. 1991;252:698–702.
49. Thiel DJ, le Du MH, Walter RL, et al. Observation of an unexpected third receptor molecule in the crystal structure of human interferon-gamma receptor complex. Structure. 2000;8:927–36.
50. Schroder K, Hertzog PJ, Ravasi T, et al. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004;75:163–89.
51. Schoenborn JR, Wilson CB. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol. 2007;96:41–101.
52. ® (Filgrastim). FDA: Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103353s5147lbl.pdf. Accessed 5 June 2014.
53. ® (Filgrastim). EMA: CHMP Assessment Report. 2. Scientific discussion, p. 4. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Public_assessment_report/human/001142/WC500093664.pdf. Accessed 5 June 2014.
54. Bonilla MA, Dale D, Zeidler C, et al. Long-term safety of treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) in patients with severe congenital neutropenias. Br J Haematol. 1994;88:723–30.
55. Cottle TE, Fier CJ, Donadieu J, et al. Risk and benefit of treatment of severe chronic neutropenia with granulocyte colony-stimulating factor. Semin Hematol. 2002;39:134–40.
56. Molineux G. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr Pharm Des. 2004;10:1235–44.
57. Metcalf D. The CSFs and cancer. Nat Rev Cancer. 2010;10:425–34.
58. ® (Pegfilgrastim). FDA: Physician package insert. http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/pegfamg013102LB.pdf. Accessed 5 June 2014.
59. Tbo-filgrastim. FDA: Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125294s0000lbl.pdf. Accessed 5 June 2014.
60. ® in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle I in breast cancer patients receiving docetaxel/doxorubicin chemotherapy. BMC Cancer. 2008;8:332–8.
61. Devine MM. Tbo-filgrastim: The first biosimilar G-CSF. Hematology/Oncology Pharmacy Association. http://www.hoparx.org/apps/ws_resource/index.php?task=view_article&article_id=137&category_id=243§ion_id=20. Accessed 5 June 2014.
62. ® (Sargramostim). FDA Advisory Committee Briefing Package, May 3, 2013. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/MedicalImagingDrugsAdvisoryCommittee/UCM350156.pdf. Accessed 5 June 2014.
63. Hercus TR, Broughton SE, Ekert PG, et al. The GM-CSF receptor family: mechanism of activation and implications for disease. Growth Factors. 2012;30:63–75.
64. ® (Oprelvekin). FDA label information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/103694s1008lbl.pdf. Accessed 5 June 2014.
65. Heinrich PC, Behrmann I, Haan S, et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003;374:1–20.
66. Vredenburgh JJ, Hussein A, Fisher D, et al. A randomized trial of recombinant human interleukin-11 following autologous bone marrow transplantation with peripheral blood progenitor cells support in patients with breast cancer. Biol Blood Marrow Transplant. 1998;4:134–41.
67. ® to prevent severe chemotherapy-induced thrombocytopenia. Stem Cells. 1998;16(suppl 2):207–23.
68. ® (Becaplermin). FDA: Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103691s5095lbl.pdf. Accessed 5 June 2014.
69. Steed DL, the Diabetic Ulcer Study Group. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. J Vasc Surg. 1995;21:71–81.
70. Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. Diabetes Care. 1998;21:822–7.
71. Barman Balfour JA, Noble S. Becaplermin. BioDrugs. 1999;11:359–64.
72. Rubin JS, Osada H, Finch PW. Purification and characterization of a newly identified growth factor specific for epithelial cells. Proc Nat Acad Sci. 1989;86:802–6.
73. ® (Palifermin). FDA: Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125103s0120lbl.pdf. Accessed 5 June 2014.
74. Blijlevens N, Sonis S. Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapy-induced mucositis. Annals Oncol. 2006;18:817–26.
75. Spielberger R, Stiff P, Bensinger W. Palifermin for oral mucositis after intensive therapy for hematologic malignancies. N Engl J Med. 2004;351:2590–8.
76. King B, Knopp E, Galan A, et al. Palifermin-associated papular eruption. Arch Dermatol. 2009;145:179–82.
77. ® (Aldesleukin). FDA label information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103293s5130lbl.pdf. http://www.bccancer.bc.ca/NR/rdonlyres/D97FCE53-F952-4718-ACAD-A2DCFF619EE5/64258/Aldesleukin_monograph_1June2013_formatted.pdf. Accessed 5 June 2014.
78. Ravaud A, Negrier S, Lakdja F, et al. Adverse effects of interleukin 2 [Article in French]. Bull Cancer. 1991;78:989–1005.
79. Aldesleukin. BC Cancer Agency Cancer Drug Manual. http://www.bccancer.bc.ca/NR/rdonlyres/D97FCE53-F952-4718-ACAD-A2DCFF619EE5/64258/Aldesleukin_monograph_1June2013_formatted.pdf. Accessed 5 June 2014.
80. Geertsen PF, Gore ME, Negrier S, et al. Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma. Br J Cancer. 2004;90:1156–62.
81. Spoerl D, Bircher AJ. Drugs that act on the immune system: cytokines and monoclonal antibodies. In: Aronson JK, editor. Side effects of drugs annual 33. Amsterdam: Elsevier; 2011. p. 777–8.
82. ® (Anakinra). FDA: Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103950s5136lbl.pdf. Accessed 5 June 2014.
83. Fleischmann RM, Schechtman J, Bennett R, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis. Arthritis Rheum. 2003;48:927–34.
84. Swart JF, Barug D, Möhlmann M, et al. The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis. Expert Opin Biol Therapy. 2010;10:1743–52.
85. ® (Epoetin alfa). FDA: Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103234Orig1s5166_103234Orig1s5266lbl.pdf. Accessed 5 June 2014.
86. Elliott SG, Foote M, Molineux G, editors. Erythropoietins, erythropoietic factors, and erythropoiesis: Molecular, cellular, preclinical, and clinical biology. 2nd ed. Basel: Birkhauser Verlag; 2009.
87. Cheung JY, Miller BA. Molecular mechanisms of erythropoietin signaling. Nephron. 2001;87:215–22.
88. Smith KJ, Bleyer AJ, Little WC, et al. The cardiovascular effects of erythropoietin. Cardiovasc Res. 2003;59:538–48.
89. McKoy JM, Stonecash RE, Cournoyer D, et al. Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion. 2008;48:1754–62.
90. McCullough PA, Barnhart HX, Inrig JK, et al. Cardiovascular toxicity of epoetin alfa in patients with chronic kidney disease. Am J Nephrol. 2013;37:549–58.
91. ® (Darbepoietin alfa). FDA: Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103951Orig1s5173_103951Orig1s5258lbl.pdf. Accessed 5 June 2014.
92. Canon J-L, Vansteenkiste J, Bodoky G, et al. Randomized, double-blind, active-controlled trial of every-3-week darbepoietin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst. 2006;98:273–84.
93. Ponikowski P, Anker SD, Szachniewicz J, et al. Effect of darbepoietin alfa on exercize tolerance in anemic patients with symptomatic chronic heart failure. J Am Coll Cardiol. 2007;49:753–62.
94. ® lumbar tapered fusion device. FDA: Summary of safety and effectiveness data. http://www.accessdata.fda.gov/cdrh_docs/pdf/P000058b.pdf. Accessed 5 June 2014.
95. Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. Growth Factors. 2004;22:233–41.
96. Bessa PC, Casal M, Reis RL. Bone morphogenetic proteins in tissue engineering: the road from the laboratory to the clinic, part I (basic concepts). J Tissue Eng Regen Med. 2008;2:1–13.
97. Carragee EJ, Hurwitz EL, Weiner BK. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J. 2011;11:471–91.
98. Woo EJ. Recombinant human bone morphogenetic protein-2: adverse events reported to the Manufacturer and User Facility Device Experience Database. Spine J. 2012;12:894–9.
99. Tannoury CA, An HS. Complications with the use of bone morphogenetic protein 2 (BMP-2) in spine surgery. Spine J. 2014;14:552–9.
100. Baldo BA. Drugs that act on the immune system: cytokines and monoclonal antibodies. In: Aronson JK, editor. Side effects of drugs annual 36. Amsterdam: Elsevier; 2015 (In press).
101. ® (Bone morphogenetic protein-7). EMA: Scientific discussion. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000293/WC500050378.pdf. Accessed 5 June 2014.
102. Marcias-Silva M, Hoodless PA, Tang SJ, et al. Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2. J Biol Chem. 1998;273:25628–36.
103. OP-1 Putty (Bone morphogenetic protein-7 putty). FDA: Post-marketing safety surveillance. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/OrthopaedicandRehabilitationDevicesPanel/UCM153635.pdf. Accessed 5 June 2014.
104. Recombinant human BMP-7/OP-1: scientific background and collaboration opportunity. http:// http://www.sbhsciences.com/BMP7_info.asp. Accessed 5 June 2014.
105. ® (Metreleptin). FDA: Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125390s000lbl.pdf. Accessed 5 June 2014.
106. Tartaglia LA. The leptin receptor. J Biol Chem. 1997;272:6093–6.
107. Myers MG, Cowley MA, Münzberg H. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol. 2008;70:537–56.
108. Ravussin E, Smith SR, Mitchell JA, et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity. 2009;17:1736–43.
109. Margetic S, Gazzola C, Pegg GG, et al. Leptin: a review of its peripheral actions and interactions. Int J Obesity. 2002;26:1407–33.
110. Fattovich G, Giustina G, Favarato S, et al. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol. 1996;24:38–47.
111. Okanoue T, Sakamoto S, Itoh Y, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol. 1996;25:283–91.
112. Dusheiko G (1997) Side effects of alpha interferon in chronic hepatitis C. Hepatology 26(Issue 3):112S–121S).
113. Fontaine H, Pol S. Side effects of interferon-α in treating hepatitis C virus infection. Transpl Proc. 2001;33:2327–9.
114. Ningrum RA. Human interferon alpha-2b: a therapeutic protein for cancer treatment. Scientifica. 2014. http://dx.doi.org/10.1155/2014/970315.
115. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today. 2005;10:1451–8.
116. Bonaccorso S, Marino V, Biondi M, et al. Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Discord. 2002;72:237–41.
117. Dieperink E, Ho SB, Thuras P, et al. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics. 2003;44:104–12.
118. Hauser P, Khosla J, Aurora H, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry. 2002;7:942–7.
119. Bonaccorso S, Marino V, Puzella A, et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol. 2002;22:86–90.
120. Kraus MR, Schafer A, Faller H, et al. Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment Pharmacol Ther. 2002;16:1091–9.
121. Capuron L, Neurauter G, Musselman DL, et al. Interferon-alpha-induced changes in tryptophan metabolism. Relationship to depression and paroxetine treatment. Biol Psychiatry. 2003;54:906–14.
122. Schaefer M, Schwaiger M, Pich M, et al. Neurotransmitter changes by interferon-alpha and therapeutic implications. Pharmacopsychiatry. 2003;36(Suppl 3):S203–6.
123. Schaefer M, Horn M, Schmidt F, et al. Correlation betweensICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon alpha. Brain Behav Immun. 2004;18:555–62.
124. Raison CL, Demetrashvili M, Capuron L, et al. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs. 2005;19:105–23.
125. Tóthová E, Kafková A, Stecová N, et al. Immune-mediated complications during interferon alpha therapy in chronic myelogenous leukemia. Neoplasma. 2002;49:91–4.
126. Yagyu H, Okada K, Sato S, et al. Pegylated interferon-alpha2b and ribavirin combination therapy induces Hashitoxicosis followed by type 1 diabetes mellitus. Diabetes Res Clin Pract. 2012;95:e52–4.
127. Pinto JL, Pinto ME. Tiroiditis autoinmune inducida por interferón en pacientes con infección por virus de la hepatitis C [Interferon-induced autoimmune thyroiditis in a patient with hepatitis C virus infection.]. Rev Peru Med Exp Salud Publica. 2011;28:382–4.
128. Yılmaz S, Cimen KA. Pegylated interferon alfa-2b induced lupus in a patient with chronic hepatitis B virus infection: case report. Clin Rheumatol. 2009;28:1241–3.
129. Ho V, Mclean A, Shaughan T. Severe systemic lupus erythematosus induced by antiviral treatment for hepatitis C. J Clin Rheumatol. 2008;14:166–8.
130. Abbott IJ, Chang CC, Skinner MJ, et al. Development and management of systemic lupus erythematosus in an HIV-infected man with hepatitis C and B co-infection following interferon therapy: a case report. J Med Case Rep. 2009;3:7289.
131. Agarwal SK, Lal C, Zaidi SH. Lupus activation with cerebritis following pegylated interferon in a hemodialysis patient. Nat Rev Nephrol. 2009;5:599–603.
132. Popescu C, Arama V, Gliga S. Acute pericarditis due to pegylated interferon alpha therapy for chronic HCV hepatitis—case report. BMC Gastroenterol. 2011;11:30.
133. Kuwara A, Ohashi M, Sugiyama M, et al. A case of reversible dilated cardiomyopathy after alpha-interferon therapy in a patient with renal cell carcinoma. Am J Med Sci. 2002;324:331–4.
134. Gupta SK, Glue P, Jacobs S, et al. Single-dose pharmacokinetics and tolerability of pegylated interferon-alpha2b in young and elderly healthy subjects. Br j Clin Pharmacol. 2003;56:131–4.
135. Gressens B, Gohy P. Pericarditis due to interferon-alpha therapy during treatment for chronic hepatitis C. Acta Gastroenterol Belg. 2004;67:301–2.
136. Rauw J, Ahmed S, Petrella T. Pericardial effusion and tamponade following interferon alpha treatment for locally advanced melanoma. Med Oncol. 2012;29:1304–7.
137. Sakabe M, Yoshioka R, Fujiki A. Sick sinus syndrome induced by interferon and ribavirin therapy in a patient with chronic hepatitis C. J Cardiol Cases. 2013;8:173–5.
138. Wang BY, Chang HH, Chen IM, et al. Peginterferon alpha-2b and acute allograft failure in a heart transplant recipient. Ann Thorac Surg. 2010;89:1645–7.
139. Kumar KS, Russo MW, Borczuk AC, et al. Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C. Am J Gastroenterol. 2002;97:2432–40.
140. Midturi J, Sierra-Hoffman M, Hurley D, et al. Spectrum of pulmonary toxicity associated with the use of interferon therapy for hepatitis C: case report and review of the literature. Clin Infect Dis. 2004;39:1724–9.
141. Kaneko R, Ogawa M, Iwata T, et al. Ursodeoxycholic acid exacerbates peginterferon-induced interstitial pneumonia in a patient with hepatitis C. Clin J Gastroenterol. 2009;2(4):296–9. doi:10.1007/s12328-009-0075-y.
142. Ando S, Kawai K, Kuriyagawa K, et al. Extremely acute exacerbation of interstitial pneumonia after interferonalpha treatment for metastatic renal cell carcinoma. Int J Clin Oncol. 2009;14:171–3.
143. Olivieri D. Desquamative interstitial pneumonitis (DIP) occurring during treatment with pegylated interferon and ribavirin. Respir Med CME. 2009;2:77–9.
144. Kang EJ, Kim DK, Jeon SR, et al. Interstitial pneumonitis in a patient with chronic hepatitis C and chronic renal failure on interferon therapy. Korean J Gastroenterol. 2011;58:47–52.
145. Foster GR, Zeuzem S, Pianko S, et al. Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin. J Viral Hepat. 2013;20:e115–23.
146. Yamamoto S, Tomita Y, Hoshida Y, et al. Interstitial pneumonia induced by combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma. J Gastroenterol. 2004;39:793–7.
147. Tokita H, Fukui H, Tanaka A, et al. Circulating KL-6 level at baseline is a predictive indicator for the occurrence of interstitial pneumonia during interferon treatment for chronic hepatitis C. Hepat Res. 2003;26:91–7.
148. Abi-Nassif S, Mark EJ, Fogel RB, et al. Pegylated interferon and ribavirin-induced pneumonitis with ARDS. Chest. 2003;124:406–10.
149. Kalambokis G, Stefanou D, Arkoumani E, et al. Fulminant bronchiolitis obliterans organizing pneumonia following 2 d of treatment with hydroxyurea, interferon-alpha and oral cytarabine ocfosfate for chronic myelogenous leukemia. Eur J Haematol. 2004;73:67–70.
150. Legroux-Crespel E, Lafaye S, Mahé E, et al. Seizures during interferon alpha therapy: three cases in dermatology [Article in French]. Ann Dermatol Venereol. 2003;130:202–4.
151. Tan EK, Chan LL, Lo YL. “Myorhythmia” slow facial tremor from chronic interferon alpha-2a usage. Neurology. 2003;61:1302–3.
152. Jabbari H, Fakharzadeh E, Merat S, et al. Bell’s palsy associated with chronic HCV infection before and during peginterferon alfa and ribavirin therapy. Arch Iran Med. 2011;14:204–5.
153. Kataoka I, Shinagawa K, Shiro Y, et al. Multiple sclerosis associated with interferon-alpha therapy for chronic myelogenous leukemia. Am J Hematol. 2002;70:149–53.
154. Matsuo T, Takabatake R. Multiple sclerosis-like disease secondary to alpha interferon. Ocul Immunol Inflamm. 2002;10:299–304.
155. LaRochelle JS, Karp BI. Restless legs syndrome due to interferon-alpha. Mov Disord. 2004;19:730–1.
156. Boonyapisit K, Katirji B. Severe exacerbation of hepatitis C-associated vasculitic neuropathy following treatment with interferon alpha: a case report and literature review. Muscle Nerve. 2002;25:909–13.
157. Hwang I, Calvit TB, Cash BD, et al. Bell’s palsy: a rare complication of interferon therapy for hepatitis C. Dig Dis Sci. 2004;49:619–20.
158. Hoare M, Woodall T, Alexander GJ. Bell’s palsy associated with IFN-alpha and ribavirin therapy for hepatitis C virus infection. J Interferon Cytokine Res. 2005;25:174–6.
159. Perlemuter G, Bodaghi B, Le Hoang P, et al. Visual loss during interferon-alpha therapy in hepatitis C virus infection. J Hepatol. 2002;37:701–2.
160. Gupta R, Singh S, Tang R, et al. Anterior ischemic optic neuropathy caused by interferon alpha therapy. Am J Med. 2002;112:683–4.
161. Vial T, Descotes J, Braun F, et al. Drugs that act on the immune system: cytokines and monoclonal antibodies. In: Aronson JK, editor. Side effects of drugs annual 28. Amsterdam: Elsevier; 2005. p. 418–9.
162. Monzani F, Caraccio N, Dardano A, et al. Thyroid autoimmunity and disfunction associated with type I interferon therapy. Clin Exp Med. 2004;3:199–210.
163. Prummel MF, Laurberg P. Interferon-alpha and autoimmune thyroid disease. Thyroid. 2003;13:547–51.
164. Tran HA, Reeves GEM, Jones TL. The natural history of interferon-a2b-induced thyroiditis and its exclusivity in a cohort of patients with chronic hepatitis C infection. Q J Med. 2009;102:117–22.
165. Soza A, Everhart JE, Ghany MG, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology. 2002;36:1273–9.
166. Herishanu Y, Trestman S, Kirgner I, et al. Autoimmune thrombocytopenia in chronic myeloid leukemia treated with interferon-alpha: differential diagnosis and possible pathogenesis. Leuk Lymphoma. 2003;44:2103–8.
167. Fujii H, Kitada T, Yamada T, et al. Life-threatening severe immune thrombocytopenia during alpha-interferon therapy for chronic hepatitis C. Hepatogastroenterology. 2003;50:841–2.
168. Arimura K, Arima N, Ohtsubo H, et al. Severe autoimmune thrombocytopenic purpura during interferon-alpha therapy for chronic myelogenous leukemia. Acta Haematol. 2004;112:217–8.
169. Andres E, Loukili NH, Ben Abdelghani M, et al. Pernicious anemia associated with interferon-alpha therapy and chronic hepatitis C infection. J Clin Gastroenterol. 2004;38:382.
170. Alabdulaaly A, Rifkind J, Solow H, et al. Rescue of interferon induced bone marrow aplasia in a patient with chronic myeloid leukemia by allogeneic bone marrow transplant. Leuk Lymphoma. 2004;45:175–7.
171. Chang CS, Yan SL, Lin HY, et al. Pure red cell aplasia caused by pegylated interferon-a-2a plus ribavirin in the treatment of chronic hepatitis C. World J Gastroenterol. 2011;17:2155–8.
172. Zuber J, Martinez F, Droz D, et al. Alpha-interferon-associated thrombotic microangiopathy: a clinicopathologic study of 8 patients and review of the literature. Med (Baltimore). 2002;81:321–31.
173. Nishimura S, Miura H, Yamada H, et al. Acute onset of nephrotic syndrome during interferon-alpha retreatment for chronic active hepatitis C. J Gastroenterol. 2002;37:854–8.
174. Ohashi N, Yonemura K, Sugiura T, et al. Withdrawal of interferon-alpha results in prompt resolution of thrombocytopenia and hemolysis but not renal failure in hemolytic uremic syndrome caused by interferon-alpha. Am J Kidney Dis. 2003;41:E10.
175. Fisher ME, Rossini M, Simmons E, et al. A woman with chronic hepatitis C infection and nephrotic syndrome who developed multiple renal lesions after interferon alfa therapy. Am J Kidney Dis. 2004;44:567–73.
176. Gordon A, Menahem S, Mitchell J, et al. Combination pegylated interferon and ribavirin therapy precipitating acute renal failure and exacerbating IgA nephropathy. Nephrol Dial Transplant. 2004;19:2155.
177. Stadler R, Mayer-da-Silva A, Bratzke B, et al. Interferons in dermatology. J Am Acad Dermatol. 1989;20:650–6.
178. Asnis LA, Gaspari AA. Cutaneous reactions to recombinant cytokine therapy. J Am Acad Dermatol. 1995;33:393–410.
179. Seckin D, Durusoy C, Sahin S. Concomitant vitiligo and psoriasis in a patient treated with interferon alfa-2a for chronic hepatitis B infection. Pediatr Dermatol. 2004;21:577–9.
180. Grossmann S, Teixeira R, de Aguiar MCF, et al. Exacerbation of oral lichen planus lesions during treatment of chronic hepatitis C with pegylated interferon and ribavirin. Eur J Gastroenterol Hepatol. 2008;20:702–6.
181. Sato M, Sueki H, Iijima M. Repeated episodes of fixed eruption 3 months after discontinuing pegylated interferon-alpha-2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus infection. Clin Exp Dermatol. 2009;34:e814–7.
182. Benito-León J, Borbujo J, Cortés L. Cutaneous mucinoses complicating interferon beta-1b therapy. Eur Neurol. 2002;47:123–4.
183. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet. 2002;359:1453–60.
184. Hartung HP, Munschauer F III, Schellekens H. Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the Proceedings of an International Consensus Conference. Eur J Neurol. 2005;12:588–601.
185. Bahri DM, Khiari H, Essouri A, et al. Systemic lupus erythematosus induced by interferon beta1 therapy in a patient with multiple sclerosis. Fundam Clin Pharmacol. 2012;26:210–1.
186. Sladkova V, Mares J, Lubenova B, et al. Drug-induced systemic lupus erythematosus in interferon beta-1b therapy. Neuro Endocrinol Lett. 2011;32:4–6.
187. Szilasiová J, Gdovinová Z, Jautová J, et al. Cutaneous vasculitis associated with interferon [beta]-1b treatment for multiple sclerosis. Clin Neuropharmacol. 2009;32:301–3.
188. Kreisler A, de Seze J, Stojkovic T, et al. Multiple sclerosis, interferon beta and clinical thyroid dysfunction. Acta Neurol Scand. 2003;107:154–7.
189. Polman CH, Jansen PH, Jansen C, et al. A rare, treatable cause of relapsing encephalopathy in an MS patient on interferon beta therapy. Neurology. 2003;61:719.
190. Guijarro C, Benito-León J, Bermejo-Pareja F. Widespread urticaria due to intramuscular interferon beta-1a therapy for multiple sclerosis. Neurol Sci. 2011;32:309–11.
191. Rosa DJ, de Matias FA, Cedrim SD, et al. Acute acneiform eruption induced by interferon beta-1b during treatment for multiple sclerosis. An Bras Dermatol. 2011;86:336–8.
192. Nathan CF, Murray HW, Wiebe ME, et al. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med. 1983;158:670–89.
193. Sidman CL, Marshall JD, Shultz LD, et al. Gammainterferon is one of several direct B cell-maturing lymphokines. Nature. 1984;309:801–3.
194. Kurzrock R, Quesada JR, Talpaz M, et al. Phase I study of multiple dose intramuscularly administered recombinant gamma interferon. J Clin Oncol. 1986;4:1101–9.
195. Kahan A, Amor B, Menkes CJ, et al. Recombinant interferon-gamma in the treatment of systemic sclerosis. Am J Med. 1989;87:273–7.
196. Honoré I, Nunes H, Groussard O, et al. Acute respiratory failure after interferon-gamma therapy of end-stage pulmonary fibrosis. Am J Respir Crit Care Med. 2003;167:953–7.
197. Raghu G, Brown KK, Bradford WZ, et al. Idiopathic Pulmonary Fibrosis Study Group. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2004;350:125–33.
198. Carvalho CR, Kairalla RA, Schettino GP. Acute respiratory failure after interferon-gamma therapy in IPF. Am J Respir Crit Care Med. 2004;169:543–4.
199. Vlachoyiannopoulos PG, Tsifetaki N, Dimitriou I, et al. Safety and efficacy of recombinant gamma interferon in the treatment of systemic sclerosis. Ann Rheum Dis. 1996;55:761–8.
200. Yamamoto N, Nishigaki K, Ban Y, et al. Coronary vasospasm after interferon administration. Br J Urol. 1998;81:916–7.
201. Ault BH, Stapleton FB, Gaber L, et al. Acute renal failure during therapy with recombinant human gamma interferon. N Engl J Med. 1988;319:1397–400.
202. Nair S, Ernstoff MS, Bahnson RR, et al. Interferon-induced reversible acute renal failure with nephrotic syndrome. Urology. 1992;39:169–72.
203. Horn TD, Altomonte V, Vogelsang G, et al. Erythroderma after autologous bone marrow transplantation modified by administration of cyclosporine and interferon gamma for breast cancer. J Am Acad Dermatol. 1996;34:413–7.
204. Metcalf D. The colony-stimulating factors and cancer. Cancer Immunol Res. 2013;1:351–6.
205. Takatsuka H, Takemoto Y, Mori A, et al. Common features in the onset of ARDS after administration of granulocyte colony-stimulating factor. Chest. 2002;121:1716–20.
206. Gertz MA, Lacy MQ, Bjornsson J, et al. Fatal pulmonary toxicity related to the administration of granulocyte colony-stimulating factor in amyloidosis: a report and review of growth factor-induced pulmonary toxicity. J Hematother Stem Cell Res. 2000;9:635–43.
207. Couderc LJ, Stelianides S, Frachon I, et al. Pulmonary toxicity of chemotherapy and G/GM-CSF: a report of five cases. Respir Med. 1999;93:65–8.
208. Hast R, Hellström-Lindberg E, Ohm L, et al. No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease. Leukemia. 2003;17:1827–33.
209. Darie C, Boutalba S, Fichter P, et al. Aortite après injections deG-CSF. Rev Med Interne. 2004;25:225–9 (Article in French).
210. Deeren DH, Zachee P, Malbrain ML. Granulocyte colony-stimulating factor-induced capillary leak syndrome confirmed by extravascular lung water measurements. Ann Hematol. 2005;84(2):89–94.
211. Wang S, Degar BA, Zieske A, et al. Hemophagocytosis exacerbated byG-CSF/GM-CSF treatment in a patient with myelodysplasia. Am J Hematol. 2004;77:391–6.
212. Kovacic JC, Macdonald P, Freund J, et al. Profound thrombocytopenia related to G-CSF. Am J Hematol. 2007;82:229–30.
213. Nuamah NM, Goker H, Kilic YA, et al. Spontaneous splenic rupture in a healthy allogeneic donor of peripheral-blood stem cell following the administration of granulocyte colony-stimulating factor (g-csf). A case report and review of the literature. Haematologica. 2006;91(5 Suppl):08.
214. Dagdas S, Ozet G, Alanoglu G, et al. Unusual extramedullary hematopoiesis in a patient receiving granulocyte colony-stimulating factor. Acta Haematol. 2006;116:198–202.
215. Socie G, Mary JY, Schrezenmeier H, et al. Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT). Blood. 2007;109:2794–6.
216. Gruschkus SK, Lairson D, Dunn JK, et al. Use of white blood cell growth factors and risk of acute myeloid leukemia or myelodysplastic syndrome among elderly patients with non-Hodgkin lymphoma. Cancer. 2010;116:5279–89.
217. Freedman MH, Alter BP. Risk of myelodysplastic syndrome and acute myeloid leukemia in congenital neutropenias. Semin Hematol. 2002;39:128–33.
218. Donadieu J, Leblanc T, Bader Meunier B, et al. Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French Severe Chronic Neutropenia Study Group. Haematologica. 2005;90:45–53.
219. Keung YK, Suwanvecho S, Cobos E. Anaphylactoid reaction to granulocyte colony-stimulating factor used in mobilization of peripheral blood stem cell. Bone Marrow Transplant. 1999;23:200–1.
220. Fitzhugh CD, Hsieh MM, Bolan CD, et al. Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium? Cytotherapy. 2009;11:464–71.
221. Kumar G, Bernstein JM, Waibel JS, et al. Sweet’s syndrome associated with sargramostim (granulocyte-macrophage colony stimulating factor) treatment. Am J Hematol. 2004;76:283–5.
222. Thompson MA, Dyson SW, Faderl S. Sweet’s syndrome in chronic lymphocytic leukemia associated with neutropenic fever and granulocyte colony stimulation factor. Am J Hematol. 2006;81:703–5.
223. Oiso N, Watanabe K, Kawada A. Granulocyte colony-stimulating factor-induced Sweet syndrome in a healthy donor. Br J Haematol. 2006;135:148.
224. Feliu J, Díaz R, Contreras F, et al. Worsening psoriasis after treatment with G-CSF in a patient with small-cell lung cancer. J Natl Cancer Inst. 1997;89:1315–6.
225. Kavanaugh A. Flare of psoriasis and psoriatic arthritis following treatment with granulocyte colony-stimulating factor. Am J Med. 1996;101:567–8.
226. 1, Cassarino DS, Jain A, et al. Disseminated vascular papules in an immunodeficient patient being treated with granulocyte colony-stimulating factor. J Am Acad Dermatol. 2003;49:105–8.
227. Alvarez-Ruiz S, Penas PF, Fernandez-Herrera J, et al. Maculopapular eruption with enlarged macrophages in eight patients receiving G-CSF or GM-CSF. J Eur Acad Dermatol Venereol. 2004;18:310–3.
228. Kurokawa I, Umehara M, Iwai T, et al. Exacerbation of palmoplantar pustulosis by granulocyte colony-stimulating factor. Int J Dermatol. 2005;44:529–30.
229. Mori T, Sato N, Watanabe R, et al. Erythema exudativum multiforme induced by granulocyte colony-stimulating factor in an allogeneic peripheral blood stem cell donor. Bone Marrow Transplant. 2000;26:239–40.
230. Prendiville J, Thiessen P, Mallory SB. Neutrophilic dermatoses in two children with idiopathic neutropenia: association with granulocyte colony-stimulating factor (G-CSF) therapy. Pediatr Dermatol. 2001;18:417–21.
231. Du X, Williams DA. Interleukin-11: Review of molecular, cell biology, and clinical use. Blood. 1997;89:3897–9.
232. Smith JW. Tolerability and side-effect profile of rhIL-11. Oncology. 2000;14(9 Suppl 8):41–7.
233. Cairo MS, Davenport V, Bessmertny O, et al. PhaseI/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study. Br J Haematol. 2005;128:49–58.
234. Hart CE, Forstrom JD, Kelly RA, et al. Two classes of PGDF receptors recognize different isoforms of PGDF. Science. 1988;240:1529–31.
235. Seifert RA, Hart CE, Phillips PE, et al. Two different subunits associate to create isoform-specific platelet-derived growth factor receptors. J Biol Chem. 1989;264:8771–8.
236. Pierce GF, Mustoe TA, Altrock BW, et al. Role of platelet-derived growth factor in wound healing. J Cell Biochem. 1991;45:319–26.
237. Pierce GF, Tarpley JE, Allman RM, et al. Tissue repair processes in healing chronic pressure ulcers treated with recombinant platelet-derived growth factor BB. Am J Pathol. 1994;145:1399–410.
238. Robson MC, Phillips LG, Thomason A, et al. Platelet-derived growth factor BB for the treatment of chronic pressure ulcers. Lancet. 1992;339:23–5.
239. ® (Becaplermin). Safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER)—October 2008. Summary of changes to contraindications and warnings. http://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety-RelatedDrugLabelingChanges/ucm121631.htm. Accessed 7 June 2014.
240. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Eng J Med. 1987;316:889–97.
241. Thompson JA, Lee DJ, Lindgren CG, et al. Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells. Cancer Res. 1989;49:235–40.
242. Lee RE, Lotze MT, Scibber JM, et al. Cardiorespiratory effects of immunotherapy with interleukin-2. J Clin Oncol. 1989;7:7–20.
243. Osanto S, Cluitmans FHM, Franks CR, et al. Myocardial injury after interleukin-2 therapy. Lancet. 1988;2:48–9.
244. Thavendiranathan P, Verhaert D, Kendra KL, et al. Fulminant myocarditis owing to high-dose interleukin-2 therapy for metastatic melanoma. Br J Radiol. 2011;84:e99–102.
245. Schwartz RN, Stover L, Dutcher J. Managing toxicities of high-dose interleukin-2. Oncology. 2002;16(11 Suppl 13):11–20.
246. Nora R, Abrams JS, Tait NS, et al. Myocardial toxic effects during recombinant interleukin-2 therapy. J Natl Cancer Inst. 1989;81:59–63.
247. Eton O, Legha SS, Bedikian AY, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol. 2002;20:2045–52.
248. MacFarlane PM, Yang JC, Guleria AJ, et al. The hematologic toxicity of interleukin-2 in patients with metastatic melanoma and renal cell carcinoma. Cancer. 1995;75:1030–7.
249. Krouse RS, Royal RE, Heywood G, et al. Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone. J Immunother. 1996;18:272–8.
250. Cormier JN, Hurst R, Vasselli J, et al. A prospective randomized evaluation of the prophylactic use of low-dose dopamine in cancer patients receiving interleukin-2. J Immunother. 1997;20:292–300.
251. Heimann DM, Schwartzentruber DJ. Gastrointestinal perforations associated with interleukin- 2 administration. J Immunother. 2004;27:254–8.
252. Pizzi C, Caraglia M, Cianciulli M, et al. Low-dose recombinant IL-2 induces psychological changes: monitoring by Minnesota Multiphasic Personality Inventory (MMPI). Anticancer Res. 2002;22:727–32.
253. Tranvan A, Pezen DS, Medenica M, et al. Interleukin-2 associated linear IgA bullous dermatosis. J Am Acad Dermatol. 1996;35:865–7.
254. Segura Huerta AA, Tordera P, Cercós AC, et al. Toxic epidermal necrolysis associated with interleukin-2. Ann Pharmacother. 2002;36:1171–4.
255. O’Reilly F, Feldman E, Yang J, et al. Recurring cutaneous eruption in a patient with metastatic renal cell carcinoma being treated with high-dose interleukin 2. J Am Acad Dermatol. 2003;48:602–4.
256. Fleischmann RM, Tesser J, Schiff MH, et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65:1006–12.
257. Turesson C, Riesbeck K. Septicemia with Staphylococcus aureus, beta-hemolytic streptococci group B and G, and Escherichia coli in a patient with rheumatoid arthritis treated with a recombinant human interleukin 1 receptor antagonist (anakinra). J Rheumatol. 2004;31:1876.
258. Settas LD, Tsimirikas G, Vosvotekas G, et al. Reactivation of pulmonary tuberculosis in a patient with rheumatoid arthritis during treatment with IL-1 receptor antagonists (anakinra). J Clin Rheumatol. 2007;13:219–20.
259. Swart JF, Barug D, Mohlmann M, et al. The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis. Expert Opin Biol Ther. 2010;10:1743–52.
260. Lequerré T, Quartier P, Rosellini D, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis. 2008;67:302–8.
261. Carter JD, Valeriano J, Vasey FB. Crohn disease worsened by anakinra administration. J Clin Rheumatol. 2003;9:276–7.
262. Desai D, Goldbach-Mansky R, Milner JD, et al. Anaphylactic reaction to anakinra in a rheumatoid arthritis patient intolerant to multiple nonbiologic and biologic disease-modifying antirheumatic drugs. Ann Pharmacother. 2009;43:967–72.
263. Livory M, Wechsler J, Revuz J, et al. Cellulite de Wells et dermohypodermite bactérienne nécrosante induites par l’anakinra [Wells’ cellulitis and bacterial necrotizing cellulitis induced by anakinra.]. Ann Dermatol Venereol. 2008;135:839–42.
264. Regula CG, Hennessy J, Clarke LE, et al. Interstitial granulomatous drug reaction to anakinra. J Am Acad Dermatol. 2008;59(2 Suppl 1):S25–7.
265. Maiese K, Chong ZZ, Shang YC. Raves and risks for erythropoietin. Cytokine Growth Factor Rev. 2008;19:145–55.
266. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with endstage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med. 1989;111:992–1000.
267. Nowicki M. Erythropoietin and hypertension. J Hum Hypertens. 1995;9:81–8.
268. Manolis AS, Tzeis S, Triantafyllou K, et al. Erythropoietin in heart failure and other cardiovascular diseases: hematopoietic and pleiotropic effects. Curr Drug Targets—Cardiovasc Haematol Disorders. 2005;5:355–75.
269. Sowade B, Sowade O, Mocks J, et al. The safety of treatment with recombinant human erythropoietin in clinical use: a review of controlled studies. Int J Mol Med. 1998;1:303–14.
270. Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer. 2004;40:2201–16.
271. Maiese K, Li F, Chong ZZ. Erythropoietin and cancer. JAMA. 2005;293:1858–9. doi:10.1001/jama.293.15.1858-b.
272. Bennett CL, Luminari S, Nissenson AR, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med. 2004;351:1403–8.
273. Weber G, Gross J, Kromminga A, et al. Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins. J Am Soc Nephrol. 2002;13:2381–3.
274. Garcia JE, Senent C, Pascual C, et al. Anaphylactic reaction to recombinant human erythropoietin. Nephron. 1993;65:636–7.
275. Bessa PC, Casal M, Reis RL. Bone morphogenetic proteins in tissue engineering: the road from the laboratory to the clinic, part II (BMP delivery). J Tissue Eng Regen Med. 2008;2:81–96.
276. Bragdon B, Moseychuk O, Saldanha S, et al. Bone morphogenetic proteins: a critical review. Cell Signal. 2011;23:609–20.
277. Ong KL, Villarrarga ML, Lau E, et al. Off-label use of bone morphogenetic proteins in the United States using administrative data. Spine (Phila, Pa). 2010;35:1794–800.
278. Cahill KS, Chi JH, Day A, et al. Prevalence, complications and hospital charges associated with the use of bone-morphogenetic proteins in spinal fusion procedures. JAMA. 2009;302:58–66.
279. Mindea SA, Shih P, Song JK. Recombinant human bone morphogenetic protein-2-induced radiculitis in elective minimally invasive transforaminal lumbar interbody fusions: a series review. Spine. 2009;34:1480–4.
280. Comer GC, Smith MW, Hurwitz EL, et al. Retrograde ejaculation after anterior lumbar interbody fusion with and without bone morphogenetic protein-2 augmentation: a 10-year cohort controlled study. Spine J. 2012;12:881–90.
281. Mroz TE, Wang JC, Hashimoto R, et al. Complications related to osteobiologics use in spine surgery: a systematic review. Spine. 2010;35(Suppl 9):S86–104.
282. ™ rhBMP-2 Matrix. Orthopedic and Rehabilitation Devices Advisory Panel. July 27, 2010. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/medicaldevices/medicaldevicesadvisorycommittee/orthopaedicandrehabilitationdevicespanel/ucm220079.pdf. Accessed 7 June 2014.
283. Koehler SM, Latridis JC, Hecht A, et al. Does BMP-2 really cause cancer? A systematic review of the literature—NASS meeting 2012. Spine J. 2012;12:S143–4.
284. Simmonds MC, Brown JV, Heirs MK, et al. Safety and effectiveness of recombinant human bone morphogenetic protein-2 for spinal fusion: a meta-analysis of individual participant data. Ann Intern Med. 2013;158:177–9.
285. Friedlaender GE, Perry CR, Cole JD, et al. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions: a prospective, randomized clinical trial comparing rhOP-1 with fresh bone autograft. J Bone Joint Surg Am. 2001;83-A(Suppl 1,Pt 2):S151–8.
286. ®) safety in anterior cervical fusion surgery. J Clin Neurosci. 2009;16:1417–20.
287. Gitelis S, Wilkins RM, Yasko AW. BMPs and cancer: Is the risk real? http://www.aaos.org/news/aaosnow/may08/research7.asp. Accessed 7 June 2014.
288. Kelesidis T, Kelesidis I, Chou S, et al. Narrative review: the role of leptin in human physiology: EMERGING clinical applications. Ann Intern Med. 2010;152:93–100.
289. Wong SL, Depaoli AM, Lee JH, et al. Leptin hormonal kinetics in the fed state: effects of adiposity, age, and gender on endogenous leptin production and clearance rates. J Clin Endocrinol Metabol. 2004;89:2672–7.
290. Javor ED, Moran SA, Ryan J, et al. Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy. J Clin Endocrinol Metabol. 2004;89:3199–207.
291. Beltrand J, Lahlou N, Charpentier T, et al. Resistance to leptin-replacement therapy in Berardinelli- Seip congenital lipodystrophy: an immunological origin. Eur J Endocrinol. 2010;162:1083–91.
292. Housa D, Housová J, Vernerová Z, et al. Adipocytokines and Cancer. Physiol Res. 2006;55:233–44.
293. Bristol-Myers Squibb, AstraZeneca: Endocrinologic and Metabolic Drugs Advisory Committee Briefing Document Metreleptin (BLA STN125390). 11 December 2013. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM377929.pdf. Accessed 7 June 2014.
294. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006;354:709–18.